peptide analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
Right after the 2026 United States intervention in Venezuela on 3 January, which led to the capture of Nicolás Maduro and Cilia Flores and their subsequent extraction from the country, White House deputy chief of staff Stephen Miller stated that the US has the right to take Greenland. His wife Katie Miller published a map of Greenland covered in the American flag with the word "SOON", which drew widespread condemnation. The Trump administration threatened military action to take control of Greenland as an option, while Secretary of State Marco Rubio stated that the goal is to buy the island from Denmark. Trump did not request any military plans for invading Greenland. A few days later, Trump claimed that "I don't need international law" and that it "may be a choice" for the United States between seizing Greenland or preserving NATO. Trump said existing treaty rights are insufficient, arguing that full ownership is "psychologically needed for success" and that the United States would "do something" on Greenland "whether they like it or not". The president also said that he would take Greenland "the hard way" if Denmark does not give up its territory, claiming that "the fact that [Denmark] had a boat land there 500 years ago doesn't mean they own the land". Trump was quoted saying "One way or the other, we are going to have Greenland" and that "we're talking about acquiring, not leasing, not having it short-term". Republican congressman Randy Fine proposed that the United States annex Greenland, in what he called the Greenland Annexation and Statehood Act.
Disuse atrophy of muscles and bones, with loss of mass and strength, can occur after prolonged immobility, such as extended bedrest, or having a body part in a cast (living in darkness for the eye, bedridden for the legs etc.). This type of atrophy can usually be reversed with exercise unless severe. There are many diseases and conditions which cause atrophy of muscle mass. For example, diseases such as cancer and AIDS induce a body wasting syndrome called cachexia, which is notable for the severe muscle atrophy seen. Other syndromes or conditions which can induce skeletal muscle atrophy are congestive heart failure and liver disease. During aging, there is a gradual decrease in the ability to maintain skeletal muscle function and mass. This condition is called sarcopenia, and may be distinct from atrophy in its pathophysiology. While the exact cause of sarcopenia is unknown, it may be induced by a combination of a gradual failure in the satellite cells which help to regenerate skeletal muscle fibers, and a decrease in sensitivity to or the availability of critical secreted growth factors which are necessary to maintain muscle mass and satellite cell survival.
In the cytosol of the cell (for example a muscle cell), the glycerol will be converted to glyceraldehyde 3-phosphate, which is an intermediate in the glycolysis, to get further oxidized and produce energy. However, the main steps of fatty acids catabolism occur in the mitochondria. Long chain fatty acids (more than 14 carbons) must be converted to fatty acyl-CoA in order to pass across the mitochondrial membrane. Fatty acid catabolism begins in the cytoplasm of cells as acyl-CoA synthetase uses the energy from cleavage of an ATP to catalyze the addition of coenzyme A to the fatty acid. The resulting acyl-CoA crosses the mitochondrial membrane to enter the process of beta oxidation. The main products of the beta oxidation pathway are acetyl-CoA (which is used in the citric acid cycle to produce energy), NADH and FADH. The process of beta oxidation requires the following enzymes: acyl-CoA dehydrogenase, enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, and 3-ketoacyl-CoA thiolase. The diagram to the left shows how fatty acids are converted into acetyl-CoA.
Sources: en.wikipedia.org
Diphenhydramine, or Diphenylhydramine, sold under the brand name Benadryl among others, is an antihistamine and sedative. Although generally considered sedating, diphenhydramine can cause paradoxical central nervous system stimulation in some individuals, particularly at higher doses. This may manifest as agitation, anxiety, or restlessness rather than sedation. It is a first-generation H1-antihistamine (i.e. it blocks histamine) with sedative effects. Diphenhydramine is also a potent anticholinergic. It is mainly used to treat allergies, insomnia, and symptoms of the common cold. It is also less commonly used for tremors in parkinsonism, and nausea. It is taken by mouth, injected into a vein, injected into a muscle, or applied to the skin. Maximal effect is typically around two hours after an oral dose, and effects can last for up to seven hours. Common side effects include sleepiness, poor coordination, and an upset stomach. There is no clear risk of harm when used during pregnancy; however, use during breastfeeding is not recommended. It was developed by George Rieveschl and put into commercial use in 1946. It is available as a generic medication. In 2023, it was the 294th most commonly prescribed medication in the United States, with more than 700,000 prescriptions. Its sedative and deliriant effects have led to some cases of recreational use.
This may have caused or contributed to the extinction of the Pleistocene megafauna, although it is also possible that the late Pleistocene extinctions were (at least in part) caused by other factors such as disease and overhunting by humans. New research suggests that the extinction of the woolly mammoth may have been caused by the combined effect of climatic change and human hunting. Scientists suggest that climate change during the end of the Pleistocene caused the mammoths' habitat to shrink, resulting in a drop in population. The small populations were then hunted out by Paleolithic humans. The global warming that occurred during the end of the Pleistocene and the beginning of the Holocene may have made it easier for humans to reach mammoth habitats that were previously frozen and inaccessible. Small populations of woolly mammoths survived on isolated Arctic islands, Saint Paul Island and Wrangel Island, until c. 3700 BP and c. 1700 BP respectively. The Wrangel Island population became extinct around the same time the island was settled by prehistoric humans. There is no evidence of prehistoric human presence on Saint Paul island (though early human settlements dating as far back as 6500 BP were found on the nearby Aleutian Islands).
Technological change is the largest cause of long-term economic growth. Throughout human history, energy production was the main constraint on economic development, and new technologies allowed humans to significantly increase the amount of available energy. First came fire, which made a wider variety of foods edible, and made it less physically demanding to digest them. Fire also enabled smelting and the use of tin, copper, and iron tools, used for hunting or tradesmanship. Then came the agricultural revolution: humans no longer needed to hunt or gather to survive, and began to settle in towns and cities, forming more complex societies, with militaries and more organized forms of religion. Technologies have contributed to human welfare through increased prosperity, improved comfort and quality of life, and medical progress, but they can also disrupt existing social hierarchies, cause pollution, and harm individuals or groups. Recent years have brought about a rise in social media's cultural prominence, with potential repercussions on democracy, as well as economic and social life. Early on, the Internet was seen as a "liberation technology" that would democratize knowledge, improve access to education, and promote democracy. Modern research has turned to investigate the Internet's downsides, including disinformation, polarization, hate speech, and propaganda. Since the 1970s, technology's impact on the environment has been criticized, leading to a surge in investment in solar, wind, and other forms of clean energy.
Jerry Andrus (1918–2007) – magician Mike Barrett (born 1968) – TV announcer of the NBA Charles B. Bellinger (1839–1905) – federal district court judge, editor of the State Rights Democrat (now the Albany Democrat-Herald) Charles Burggraf Architect that spent most of his professional career in Albany. Dyrol Burleson 1500 m Olympian George Earle Chamberlain (1854–1928) – 11th Governor of Oregon Daveigh Chase (1990-2026) – actress Abigail Scott Duniway (1834–1915) – writer, newspaper publisher, and women's rights advocate Neil Elshire – former NFL defensive end, Minnesota Vikings Members of Falling Up – Christian rock band Alan L. Hart (1890–1962) – physician and novelist, raised in Albany Glenn L. Jackson (1902-1980) - Businessman and Chairman of the Oregon State Highway Commission Dave Johnson (born 1963) – Olympic athlete and former West Albany High School teacher Percy R. Kelly (1870–1949) – American attorney and jurist in the state of Oregon Ardyth Kennelly (1912–2005) – novelist Frank Morse (born 1943) – politician Sam Shoen (1916–1999) – founder of U-Haul Corp., operated a barbershop in the St. Francis Hotel at First Ave. and Ferry St. while a student at Oregon State College in the early 1940s. Delazon Smith (1816–1860) – politician Elmo Smith (1909–1968) – 27th Governor of Oregon Evelyn Waldren (1908–1986) – aviation pioneer James K. Weatherford (1850–1935) – Speaker of the Oregon House of Representatives (1876) and State Senator Mae Yih (born 1928) – member of the Oregon Legislative Assembly
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.